Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

M.A. Davies; P. Saiag; C. Robert; J.-J. Grob; K.T. Flaherty; A. Arance; V. Chiarion-Sileni; L. Thomas; T. Lesimple; L. Mortier; S.J. Moschos; D. Hogg; I. Márquez-Rodas; M. Del Vecchio; C. Lebbé; N. Meyer; Y. Zhang; Y. Huang; B. Mookerjee; G.V. Long

doi:10.1016/S1470-2045(17)30429-1

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

M.A. Davies, P. Saiag, C. Robert, J.-J. Grob, K.T. Flaherty, A. Arance, V. Chiarion-Sileni, L. Thomas, T. Lesimple, L. Mortier, S.J. Moschos, D. Hogg, I. Márquez-Rodas, M. Del Vecchio, C. Lebbé, N. Meyer, Y. Zhang, Y. Huang, B. Mookerjee, G.V. Long

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	863-873
Number of pages	11
Journal	The Lancet Oncology
Volume	18
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(17)30429-1
Publication status	Published - 2017

Access to Document

10.1016/S1470-2045(17)30429-1

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020120926&doi=10.1016%2fS1470-2045%2817%2930429-1&partnerID=40&md5=5171c873e2b3d72334b35d8adcad55ba

Cite this

Davies, M. A., Saiag, P., Robert, C., Grob, J-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., Moschos, S. J., Hogg, D., Márquez-Rodas, I., Del Vecchio, M., Lebbé, C., Meyer, N., Zhang, Y., Huang, Y., Mookerjee, B., & Long, G. V. (2017). Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet Oncology, 18(7), 863-873. https://doi.org/10.1016/S1470-2045(17)30429-1

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. / Davies, M.A.; Saiag, P.; Robert, C.; Grob, J.-J.; Flaherty, K.T.; Arance, A.; Chiarion-Sileni, V.; Thomas, L.; Lesimple, T.; Mortier, L.; Moschos, S.J.; Hogg, D.; Márquez-Rodas, I.; Del Vecchio, M.; Lebbé, C.; Meyer, N.; Zhang, Y.; Huang, Y.; Mookerjee, B.; Long, G.V.

In: The Lancet Oncology, Vol. 18, No. 7, 2017, p. 863-873.

Research output: Contribution to journal › Article › peer-review

Davies, MA, Saiag, P, Robert, C, Grob, J-J, Flaherty, KT, Arance, A, Chiarion-Sileni, V, Thomas, L, Lesimple, T, Mortier, L, Moschos, SJ, Hogg, D, Márquez-Rodas, I, Del Vecchio, M, Lebbé, C, Meyer, N, Zhang, Y, Huang, Y, Mookerjee, B & Long, GV 2017, 'Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial', The Lancet Oncology, vol. 18, no. 7, pp. 863-873. https://doi.org/10.1016/S1470-2045(17)30429-1

Davies, M.A. ; Saiag, P. ; Robert, C. ; Grob, J.-J. ; Flaherty, K.T. ; Arance, A. ; Chiarion-Sileni, V. ; Thomas, L. ; Lesimple, T. ; Mortier, L. ; Moschos, S.J. ; Hogg, D. ; Márquez-Rodas, I. ; Del Vecchio, M. ; Lebbé, C. ; Meyer, N. ; Zhang, Y. ; Huang, Y. ; Mookerjee, B. ; Long, G.V. / Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. In: The Lancet Oncology. 2017 ; Vol. 18, No. 7. pp. 863-873.

@article{02adae2a5bf9405c9761ca2fbc8fcfc0,

title = "Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial",

author = "M.A. Davies and P. Saiag and C. Robert and J.-J. Grob and K.T. Flaherty and A. Arance and V. Chiarion-Sileni and L. Thomas and T. Lesimple and L. Mortier and S.J. Moschos and D. Hogg and I. M{\'a}rquez-Rodas and {Del Vecchio}, M. and C. Lebb{\'e} and N. Meyer and Y. Zhang and Y. Huang and B. Mookerjee and G.V. Long",

note = "cited By 11",

year = "2017",

doi = "10.1016/S1470-2045(17)30429-1",

language = "Non definita",

volume = "18",

pages = "863--873",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

TY - JOUR

T1 - Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

AU - Davies, M.A.

AU - Saiag, P.

AU - Robert, C.

AU - Grob, J.-J.

AU - Flaherty, K.T.

AU - Arance, A.

AU - Chiarion-Sileni, V.

AU - Thomas, L.

AU - Lesimple, T.

AU - Mortier, L.

AU - Moschos, S.J.

AU - Hogg, D.

AU - Márquez-Rodas, I.

AU - Del Vecchio, M.

AU - Lebbé, C.

AU - Meyer, N.

AU - Zhang, Y.

AU - Huang, Y.

AU - Mookerjee, B.

AU - Long, G.V.

N1 - cited By 11

PY - 2017

Y1 - 2017

U2 - 10.1016/S1470-2045(17)30429-1

DO - 10.1016/S1470-2045(17)30429-1

M3 - Articolo

VL - 18

SP - 863

EP - 873

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -